Your SlideShare is downloading. ×
0
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12

283

Published on

A joint organization of LIEGE CREATIVE, Interface Entreprises-Université Liège and GIGA, based on shared experiences and available support in order to help researchers accessing these funding …

A joint organization of LIEGE CREATIVE, Interface Entreprises-Université Liège and GIGA, based on shared experiences and available support in order to help researchers accessing these funding opportunities.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
283
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Les points sur les i Health researchers : double your funding opportunities and those of your U.S. partners, by targeting jointly E.C. and N.I.H. projectsDr Claire SKENTELBERY – Secretary General, European Biotechnology FoundationProf. J. BALTHAZART and Dr Julie BAKKER, ULg-GIGA NeurosciencesIsabelle RAUSIN, ULg-Interface and Jérôme EECKHOUT, ULg-ARD
  • 2. Avec le soutien de :
  • 3. Building transatlanticresearch partnershipsClaire SkentelberyEuropean Biotechnology Network www.european-biotechnology.net 15.2.2012 1
  • 4. Mission for today•  Introduce European Biotechnology Network•  Understand tools available to build US research partnerships•  Suitability for your work•  Plan 2012 opportunities•  Get to work! www.european-biotechnology.net 15.2.2012 2
  • 5. Getting introduced•  Cross sectoral network in biotech•  Mission to facilitate partnership•  Delivering biotechnology – critical mass, accelerated pace•  Biotechnology Funding Hub•  Strong focus on SME/industry inclusion•  Global focus for Europe www.european-biotechnology.net 15.2.2012 3
  • 6. Liege as a Network member•  For researchers and support staff•  Sign up to the Network each and every one!•  Free subscription to European Biotechnology News – sign up to get your personal copy•  Funding Hub news – get the latest updates•  Free access to Network events/training•  Priority speaker places at events•  Direct assistance in project development•  Hub around which we can build projects www.european-biotechnology.net 15.2.2012 4
  • 7. Offer today•  Doing the business in the US! –  March 29th, Brussels –  Small intensive workshop –  Logistics of building a successful US partnership –  €100 Corporate members•  Building Transatlantic partnerships –  March 30th, Brussels –  NIH, EC, DoD, Gates Foundation –  Broader look at funding and experiences –  2 free places for Corporate members www.european-biotechnology.net 15.2.2012 5
  • 8. Biotechnology Funding Hub•  Track funding open to SMEs in Europe; EC, Eurostars, eurotransbio, NIH, DoD•  Mission to build collaborative partnerships•  Work with members to find projects and develop proposals•  Training/advice/signposting•  Skype/phone surgeries www.european-biotechnology.net 15.2.2012 6
  • 9. Opportunities•  National Institutes of Health•  Department of Defense•  Last call in FP7 www.european-biotechnology.net 15.2.2012 7
  • 10. DoD 2012 – in a nutshell•  Secret funding tool – wide funding range•  Projects, fellowships – open to global application•  Few active in Europe, almost all in UK•  Significant opportunities for partnered applications: –  Across all biology –  Diagnostics, vaccines, disease management, real time & remote technologies –  Projects in Europe include breast cancer, immunotherapy, lung cancer etc. 8 topics currently open www.grants.gov www.european-biotechnology.net 15.2.2012 8
  • 11. FP7 2012 – in a nutshell –  Last call in 2012 –  Lots of support in Liege –  Opportunity to engage US partners for EC projects - € directly from Brussels –  Strong SME partnership opportunity –  EBN working with NIH to matchmake research for FP7 www.european-biotechnology.net 15.2.2012 9
  • 12. NIH: Where to start?•  NIH enormous research and funding platform•  Aim of talk to address from practical perspective –  What is it? –  Opportunities for me –  How to access projects –  Chances of success –  Best approach –  Finding partners –  Who can help me? www.european-biotechnology.net 15.2.2012 10
  • 13. What is NIH?•  NIH’s mission is to seek fundamental knowledge about the nature and behaviour of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.•  Broad programme – basic-applied/clinical research•  $31.2 billion annual budget – squeezed in 2011/12 www.european-biotechnology.net 15.2.2012 11
  • 14. Institutes of the NIH•  27!•  Cancer, eye, Heart lung and blood, human genome, ageing, alcohol abuse, allergy & infectious disease, arthritis & skin disease, imaging and bioengineering, child health, deafness & communication disorders, dental & craniofacial, diabetes, digestive & kidney diseases, drug abuse, env health, general medical sciences, mental health, neurological disorders & stroke, nursing, rare/neglected diseases•  New - National Center for Advancing Translational Sciences’ www.european-biotechnology.net 15.2.2012 12
  • 15. Each Institute has…•  Own mission and structure•  Own research funding programme and budget•  Dedicated funding or joint funding with other Institutes•  Budget varies hugely www.european-biotechnology.net 15.2.2012 13
  • 16. Opportunities open for me?•  Focus on main funding programmes suitable•  Programmes launched – open 4 years•  3 deadlines/year – multiple application opportunities•  Main programmes open to non-US applicationFor non-US success, must either: –  Be not available in US –  Significant benefit to US research www.european-biotechnology.net 15.2.2012 14
  • 17. Programme announcements (PA)•  General areas of high priority•  Proposals submitted at any time of year•  Evaluated 3 times/year•  Evaluation timescale: –  Scientific merit review: 2-3 months –  Advisory Council: 4-5 months –  Earliest start: 6-7 months 720 PAs open NOW! www.european-biotechnology.net 15.2.2012 15
  • 18. Requests for Application (RFA)•  More specific research applications•  Often single deadline 92 RFAs open now! www.european-biotechnology.net 15.2.2012 16
  • 19. Project types - R21 –  Exploratory, groundbreaking research –  Max 2 years –  Max $275,000 –  Encouraged to contact NIH during development stage www.european-biotechnology.net 15.2.2012 17
  • 20. Project types – R01 –  ‘Original’ proposal type –  PI nominates topic and focus within programme announcement –  Covers salary, equipment, consultants, contract services, indirect costs, travel –  No max cost BUT: •  €25,000 modules up to module limit of $250k •  Max 5 periods – usually 12 months each •  All non-US applicants must have detailed budget –  1 resubmission allowed –  Encouraged to contact NIH www.european-biotechnology.net 15.2.2012 18
  • 21. Project types - P01•  Research program projects•  Broad based•  Multidisciplinary•  Long term•  All address different elements of common objectives•  Industry encouraged – non-US also•  No budget max unless stated www.european-biotechnology.net 15.2.2012 19
  • 22. Funding level/success rates?Varies between Institute: 2010 examples•  NCI: 17% - $516 million•  NIAID (allergy/infectious disease): 24% - $506 million•  NHLBI (heart/lung/blood): 20% - $416 million•  NIGMS (general): 27% - $336 million•  NIDDK (diabetes/digestive/kidney): 26% - $333 millionThis counts project renewal: higher % for thoseNew project: More like 10% success www.european-biotechnology.net 15.2.2012 20
  • 23. Proposal contents•  Pleasingly similar between all!•  Get familiar with PHS398 – core example www.european-biotechnology.net 15.2.2012 21
  • 24. Proposal core elements –  Budget for initial/whole –  Research plan: •  Aims •  Strategy – see next slide •  Inclusion – women/minorities •  Enrolment •  Agent research •  Leadership plan •  Consortium/contractual plan www.european-biotechnology.net 15.2.2012 22
  • 25. Research strategy contents•  Significance (problem, scientific advance, impact)•  Innovation (changes to current practice, novelty and advantage)•  Approach (strategy, method, analyses, data collection, risk management, hazards)•  Preliminary studies for new applicationsNo max length: detailed, clear and concise! www.european-biotechnology.net 15.2.2012 23
  • 26. Example Programme announcement www.european-biotechnology.net 15.2.2012 24
  • 27. PA cont www.european-biotechnology.net 15.2.2012 25
  • 28. PA cont www.european-biotechnology.net 15.2.2012 26
  • 29. Quick summary•  Each call VERY detailed•  Expectations listed•  Eligibility defined•  Direct contact details for each•  Deadlines•  All hyperlinked www.european-biotechnology.net 15.2.2012 27
  • 30. Information overload?•  Looked at: –  Institutes –  Funding programmes –  Project types –  Success rates•  What now? www.european-biotechnology.net 15.2.2012 28
  • 31. If I was doing this…….•  First time European applicant?•  Find suitable call topic•  Find European organisations already playing in US – several in the room!•  Find US partners you KNOW and are active in NIH•  Understand history of funding in this area•  Try and join/develop US-led proposal•  Go prepared to a key US conf and partner www.european-biotechnology.net 15.2.2012 29
  • 32. Resources to use•  Searchable database on NIH websitehttp://projectreporter.nih.gov/reporter.cfm•  Many funding reports available•  Find groups active in your field – great starting point www.european-biotechnology.net 15.2.2012 30
  • 33. Thank you"Good hunting!" www.european-biotechnology.net 15.2.2012 31

×